Country: United States
Language: English
Source: NLM (National Library of Medicine)
POTASSIUM CHLORIDE (UNII: 660YQ98I10) (POTASSIUM CATION - UNII:295O53K152, CHLORIDE ION - UNII:Q32ZN48698)
VistaPharm, Inc.
POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 20 meq in 15 mL
ORAL
PRESCRIPTION DRUG
Potassium Chloride is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction are insufficient. Potassium chloride is contraindicated in patients on potassium sparing diuretics There are no human data related to use of Potassium Chloride during pregnancy, and animal studies have not been conducted. Potassium supplementation that does not lead to hyperkalemia is not expected to cause fetal harm. The background risk for major birth defects and miscarriage in the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Risk Summary The normal potassium ion content of human milk is about 13 mEq per liter. Since potassium from oral supplements such a
Potassium Chloride Oral Solution, is an orange solution available as follows: (NDC# 66689-047-01), packaged in trays of 10 unit-dose cups each. NDC# 66689-047-30: Cases contains 30 unit-dose cups of 15 mL NDC# 66689-047-50: Cases contains 50 unit-dose cups of 15 mL NDC# 66689-047-80: Cases contains 80 unit-dose cups of 15 mL NDC# 66689-047-99: Cases contains 100 unit-dose cups of 15 mL (NDC# 66689-048-01), packaged in trays of 10 unit-dose cups each. NDC# 66689-048-30: Cases contains 30 unit-dose cups of 30 mL NDC# 66689-048-50: Cases contains 50 unit-dose cups of 30 mL NDC# 66689-048-80: Cases contains 80 unit-dose cups of 30 mL NDC# 66689-048-99: Cases contains 100 unit-dose cups of 30 mL Storage Store at Controlled Room Temperature, 25°C (77°F); excursions are permitted to 15° - 30°C (59° - 86°F). Dispense in a tight, light-resistant container as defined in the USP PROTECT from LIGHT and FREEZING. KEEP THIS AND ALL MEDICATION OUT OF THE REACH OF CHILDREN.
New Drug Application
POTASSIUM CHLORIDE- POTASSIUM CHLORIDE SOLUTION VISTAPHARM, INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE POTASSIUM CHLORIDE SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR POTASSIUM CHLORIDE. POTASSIUM CHLORIDE ORAL SOLUTION INITIAL U.S. APPROVAL: 1948 INDICATIONS AND USAGE Potassium Chloride is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction are insufficient. (1) DOSAGE AND ADMINISTRATION Dilute prior to administration. (2.1, 5.1) Monitor serum potassium and adjust dosage accordingly (2.2, 2.3) _Treatment of hypokalemia:_ Adults: Initial doses range from 40-100 mEq/day in 2-5 divided doses: limit doses to 40 mEq per dose. Total daily dose should not exceed 200 mEq (2.2) Pediatric patients aged birth to 16 years old: 2-4 mEq/kg/day in divided doses; not to exceed 1 mEq/kg as a single dose or 40 mEq whichever is lower; if deficits are severe or ongoing losses are great, consider intravenous therapy. Total daily dose should not exceed 100 mEq (2.3) _Maintenance or Prophylaxis of hypokalemia:_ Adults: Typical dose is 20 mEq per day (2.2) Pediatric patients aged birth to 16 years old: typical dose is 1 mEq/kg/day. Do not to exceed 3 mEq/kg/day (2.3) DOSAGE FORMS AND STRENGTHS Oral Solution: 10%; 1.3 mEq potassium per mL (3) CONTRAINDICATIONS Concomitant use with potassium sparing diuretics. (4) WARNINGS AND PRECAUTIONS Gastrointestinal Irritation: Dilute before use, take with meals (5.1) ADVERSE REACTIONS Most common adverse reactions are nausea, vomiting, flatulence, abdominal pain/discomfort, and diarrhea. (6) TO REPORT SUSPECTED ADVERSE REACTIONS, CONTACT VISTAPHARM, INC. AT 1-888-655-1505 OR FDA AT 1-800-FDA-1088 OR WWW.FDA.GOV/MEDWATCH. DRUG INTERACTIONS Potassium sparing diuretics: Avoid concomitant use (7.1) Renin-angiotensin-aldosterone inhibitors:Monitor for hyperkalemia (7.2) Nonste Read the complete document